Brain Tumor Assessment: Integrating PET/Computed Tomography and MR Imaging Modalities

Area of Science:

• Neuro-oncology
• Medical Imaging
• Nuclear Medicine

Background:

• Magnetic Resonance (MR) imaging is the primary modality for brain tumor assessment.
• Positron Emission Tomography (PET) imaging plays a crucial, complementary role in neuro-oncology.
• Several PET tracers are under development, but 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) and O-(2-[18F]-fluoroethyl)-l-tyrosine ([18F]FET) are clinically established.

Purpose of the Study:

• To provide an overview of the current clinical status of brain tumor imaging.
• To emphasize the specific role and advancements in PET imaging for brain tumors.
• To discuss the growing acceptance and utility of [18F]FET PET due to its superior sensitivity.

Main Methods:

• Review of clinical applications of established PET tracers for brain tumors.
• Comparison of [18F]FDG and [18F]FET PET imaging in neuro-oncology.
• Discussion on the sensitivity and clinical acceptance of [18F]FET.

Main Results:

• [18F]FDG and [18F]FET are the most clinically established PET tracers for brain tumors.
• [18F]FET PET imaging demonstrates higher sensitivity compared to other tracers.
• Increased clinical acceptance of [18F]FET PET for brain tumor evaluation.

Conclusions:

• PET imaging, especially with [18F]FET, is a valuable tool in the clinical management of brain tumors.
• The higher sensitivity of [18F]FET enhances diagnostic accuracy in neuro-oncology.
• This overview underscores the importance of PET imaging in the current clinical landscape of brain tumor assessment.